Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.

Lundershausen R, Müller S, Hashim M, Kienhöfer J, Kipper S, Wilke T

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association29 Aug 2018Cited by 5 (Europe PMC)

PMID30157532DOI10.1055/a-0636-3961PepBankPUB-30157532

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, ADDQoL average weighted impact scores improved numerically in both groups at 52 weeks, with no significant difference between liraglutide and insulin.
In plain wordsIn adults with type 2 diabetes, quality-of-life scores improved in both groups, with no significant difference between liraglutide and insulin.
Peptide
Liraglutide
Outcome
No significant changeADDQoL average weighted impact score
Study
n = 1,260
Comparator
Insulin
Analysis
Primary
Outcome group
Quality of life · Whole body
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
ADDQoL mean difference, liraglutide vs insulin
0.159 score
52 weeks
Source sentences
Summary
ADDQoL average weighted impact scores improved numerically in both groups from baseline to 52 weeks (mean difference [95% confidence interval], liraglutide vs. insulin: 0.159 [-0.023;0.340]; not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753201
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, changes in general wellbeing and five ADDQoL domains significantly favored liraglutide over insulin.
In plain wordsIn adults with type 2 diabetes, general wellbeing and five quality-of-life areas improved more with liraglutide than with insulin.
Peptide
Liraglutide
Outcome
IncreaseADDQoL general wellbeing and five domains
Study
n = 1,260
Comparator
Insulin
Outcome group
Quality of life · Whole body
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Changes in general wellbeing and five ADDQoL domains significantly favored liraglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753202
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the remaining 14 ADDQoL domains did not differ significantly between liraglutide and insulin.
In plain wordsIn adults with type 2 diabetes, 14 other quality-of-life areas did not differ significantly between liraglutide and insulin.
Peptide
Liraglutide
Outcome
No significant changeRemaining 14 ADDQoL domains
Study
n = 1,260
Comparator
Insulin
Outcome group
Quality of life · Whole body
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Source sentences
Summary
remaining 14 domains, not significant).
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753203
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, HbA1c fell by 1.2% with liraglutide, a smaller reduction than the 2.0% with insulin.
In plain wordsIn adults with type 2 diabetes, HbA1c fell less with liraglutide than with insulin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction from baseline
Study
n = 1,260
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2%
liraglutide
HbA1c change
−2%
insulin
Source sentences
Summary
HbA_1c reductions were greater with insulin than liraglutide (-2.0% vs. -1.2%; p<0.01
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753204
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, mean HbA1c after 52 weeks was 7.2% in both the liraglutide and insulin groups.
In plain wordsIn adults with type 2 diabetes, average HbA1c after 52 weeks was the same with liraglutide and insulin.
Peptide
Liraglutide
Outcome
No significant changeMean HbA1c after 52 weeks
Study
n = 1,260
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
HbA1c at 52 weeks
7.2%
both groups
Source sentences
Summary
however, mean HbA_1c after 52 weeks was 7.2% in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753205
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body mass index fell with liraglutide (-1.54 kg/m2) but rose with insulin (+0.27 kg/m2).
In plain wordsIn adults with type 2 diabetes, body mass index fell with liraglutide but rose slightly with insulin.
Peptide
Liraglutide
Outcome
DecreaseBody mass index change
Study
n = 1,260
Comparator
Insulin
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
BMI change
−1.54 kg/m2
liraglutide
BMI change
0.27 kg/m2
insulin
Source sentences
Summary
Compared with insulin, liraglutide significantly decreased body mass index (-1.54 kg/m² vs. +0.27 kg/m²; p<0.001
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753206
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, liraglutide decreased systolic blood pressure more than insulin.
In plain wordsIn adults with type 2 diabetes, systolic blood pressure fell more with liraglutide than with insulin.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 1,260
Comparator
Insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
Systolic blood pressure change
−5.03 mmHg
liraglutide
Systolic blood pressure change
−1.03 mmHg
insulin
Source sentences
Summary
systolic blood pressure (-5.03 mmHg vs. -1.03 mmHg
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753207
08HumanObservational studySafety outcome
In adults with type 2 diabetes, non-severe hypoglycemia was less frequent with liraglutide than with insulin at 52 weeks.
In plain wordsIn adults with type 2 diabetes, mild low blood sugar happened less often with liraglutide than with insulin.
Peptide
Liraglutide
Outcome
DecreaseNon-severe hypoglycemia at 52 weeks
Study
n = 1,260
Comparator
Insulin
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
Non-severe hypoglycemia
0.85%
liraglutide
Non-severe hypoglycemia
4.55%
insulin
Source sentences
Summary
non-severe hypoglycemia (0.85% vs. 4.55% at 52 weeks; p<0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753208
09HumanObservational studySafety outcome
In adults with type 2 diabetes, adverse drug reactions were reported for less than 3% of patients in both groups.
In plain wordsIn adults with type 2 diabetes, fewer than 3% of patients in either group reported adverse drug reactions.
Peptide
Liraglutide
Outcome
Not applicableAdverse drug reactions
Study
n = 1,260
Outcome group
Adverse events · Whole body
Studied dose
up to 1.8 mg daily · 52 weeksAs given in this study (human).
Measurements
Adverse drug reactions
< 3%
both groups
Source sentences
Summary
Adverse drug reactions were reported for<3% of patients in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician's decision and followed for 52 weeks.
Report a problemFND-3015753209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01484262

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Novo Nordisk A/Sn = 1,34414 Nov 2011 to 31 Oct 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 1 Nov 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.